Journal
SUPPORTIVE CARE IN CANCER
Volume 19, Issue 8, Pages 1079-1095Publisher
SPRINGER
DOI: 10.1007/s00520-011-1197-6
Keywords
Rash; Xerosis; Paronychia; Pruritus; Radiation dermatitis; Mucositis; EGFR inhibitors; Recommendations
Funding
- Bristol-Myers Squibb
- Evolife
- OSI Pharmaceuticals, Inc.
- Amgen, Inc.
- Dermatology Foundation
- Hana Biosciences
- Merck
- Sharp
- Dohme Corporation
Ask authors/readers for more resources
Background Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities. Methods A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities. Results Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible. Conclusion Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients' health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available